HFS
NBIX icon

Hantz Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

Hantz Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
6,706
+3,275
+95% +$486K 0.02% 482
2026
Q1 		$452K Buy
3,431
+77
+2% +$10.2K 0.01% 669
2025
Q4 		$476K Buy
3,354
+1,349
+67% +$195K 0.01% 607
2025
Q3 		$281K Buy
2,005
+693
+53% +$93.9K ﹤0.01% 659
2025
Q2 		$165K Buy
1,312
+683
+109% +$78.3K ﹤0.01% 648
2025
Q1 		$70K Sell
629
-49
-7% -$6.21K ﹤0.01% 657
2024
Q4 		$93K Sell
678
-249
-27% -$30.8K ﹤0.01% 614
2024
Q3 		$107K Hold
927
– – ﹤0.01% 609
2024
Q2 		$128K Sell
927
-15
-2% -$2.06K ﹤0.01% 593
2024
Q1 		$130K Sell
942
-132
-12% -$18K ﹤0.01% 590
2023
Q4 		$142K Sell
1,074
-102
-9% -$11.7K ﹤0.01% 580
2023
Q3 		$132K Sell
1,176
-321
-21% -$33.8K ﹤0.01% 573
2023
Q2 		$141K Sell
1,497
-106,276
-99% -$10.4M ﹤0.01% 561
2023
Q1 		$10.9M Sell
107,773
-2,003
-2% -$208K 0.3% 98
2022
Q4 		$13.1M Sell
109,776
-46,783
-30% -$5.48M 0.4% 68
2022
Q3 		$16.6M Buy
156,559
+1,399
+0.9% +$142K 0.57% 36
2022
Q2 		$15.1M Buy
155,160
+4,022
+3% +$371K 0.51% 42
2022
Q1 		$14.2M Buy
151,138
+89,462
+145% +$7.58M 0.42% 68
2021
Q4 		$5.25M Buy
61,676
+5,633
+10% +$518K 0.15% 174
2021
Q3 		$5.38M Buy
56,043
+7,526
+16% +$711K 0.18% 161
2021
Q2 		$4.72M Buy
48,517
+1,615
+3% +$155K 0.17% 159
2021
Q1 		$4.56M Buy
46,902
+1,102
+2% +$116K 0.19% 154
2020
Q4 		$4.39M Buy
45,800
+2,930
+7% +$283K 0.2% 153
2020
Q3 		$4.12M Buy
+42,870
New +$4.96M 0.21% 141

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hantz Financial Services's NBIX Position: Q2 2026 in Review

Hantz Financial Services increased its Neurocrine Biosciences (NBIX) stake by 95% in Q2 2026, buying an estimated $486K and bringing the position to 6,706 shares worth $1.13M. The position accounts for 0.02% of the portfolio, ranked #482.

Hantz Financial Services first reported a position in NBIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $16.6M in Q3 2022. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Hantz Financial Services held 6,706 shares of Neurocrine Biosciences worth $1.13M as of Q2 2026.
  • Hantz Financial Services bought 3,275 Neurocrine Biosciences shares in Q2 2026, an estimated $486K.
  • Neurocrine Biosciences made up 0.02% of Hantz Financial Services's portfolio in Q2 2026, its #482 holding.
  • Hantz Financial Services first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 24 quarters since.
  • Hantz Financial Services's Neurocrine Biosciences position peaked at $16.6M in Q3 2022.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.